Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2017 | Review article

The K_ATP channel in migraine pathophysiology: a novel therapeutic target for migraine

Authors: Mohammad Al-Mahdi Al-Karagholi, Jakob Møller Hansen, Johanne Severinsen, Inger Jansen-Olesen, Messoud Ashina

Published in: The Journal of Headache and Pain | Issue 1/2017

Abstract

Background

To review the distribution and function of K_ATP channels, describe the use of K_ATP channels openers in clinical trials and make the case that these channels may play a role in headache and migraine.

Discussion

K_ATP channels are widely present in the trigeminovascular system and play an important role in the regulation of tone in cerebral and meningeal arteries. Clinical trials using synthetic K_ATP channel openers report headache as a prevalent-side effect in non-migraine sufferers, indicating that K_ATP channel opening may cause headache, possibly due to vascular mechanisms. Whether K_ATP channel openers can provoke migraine in migraine sufferers is not known.

Conclusion

We suggest that K_ATP channels may play an important role in migraine pathogenesis and could be a potential novel therapeutic anti-migraine target.

Noma A (1983) ATP-regulated K+ channels in cardiac muscle. Nature 305:147–148. doi:10.1038/305147a0 CrossRef

Aguilar-Bryan L, Bryan J (1999) Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 20:101–135. doi:10.1210/er.20.2.101 PubMed

Dunn-Meynell AA, Rawson NE, Levin BE (1998) Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 814:41–54. doi:10.1016/S0006-8993(98)00956-1 CrossRefPubMed

Yamada K, Inagaki N (2005) Neuroprotection by KATP channels. J Mol Cell Cardiol 38:945–949. doi:10.1016/j.yjmcc.2004.11.020 CrossRefPubMed

Saito T, Fujiwara Y, Fujiwara R, et al (2002) Experimental biology 2001 symposium potassium channels that regulate vascular tone : which are the important players ? ROLE OF AUGMENTED EXPRESSION OF INTERMEDIATE- CONDUCTANCE CA 2 + −ACTIVATED K + CHANNELS IN. 324–329

Ashina M, Hansen JM, Olesen J (2013) Pearls and pitfalls in human pharmacological models of migraine: 30 years’ experience. Cephalalgia 33:540–553. doi:10.1177/0333102412475234 CrossRefPubMed

Clement JP, Kunjilwar K, Gonzalez G et al (1997) Association and stoichiometry of K(ATP) channel subunits. Neuron 18:827–838. doi:10.1016/S0896-6273(00)80321-9 CrossRefPubMed

Shyng S-L, Nichols CG (1997) Octameric stoichiometry of the K _ATP Channel complex. J Gen Physiol 110:655–664. doi:10.1085/jgp.110.6.655 CrossRefPubMedPubMedCentral

Rubaiy HN (2016) The therapeutic agents that target ATP-sensitive potassium channels. Acta Pharma 66:23–34. doi:10.1515/acph-2015-0040 CrossRef

10.

Faraci FM, Sobey CG (1998) Role of potassium channels in regulation of cerebral vascular tone. J Cereb Blood Flow Metab 18:1047–1063. doi:10.1097/00004647-199810000-00001 CrossRefPubMed

11.

Chrissobolis S, Sobey CG (2003) Inwardly rectifying potassium channels in the regulation of vascular tone. Curr Drug Targets 4:281–289CrossRefPubMed

12.

Henn MC, Janjua MB, Zhang H et al (2016) Increased tolerance to stress in cardiac expressed gain-of-function of adenosine triphosphate–sensitive potassium channel subunit Kir6.1. J Surg Res 206:460–465. doi:10.1016/j.jss.2016.08.043 CrossRefPubMed

13.

Gozalov A, Petersen KA, Mortensen C et al (2005) Role of KATP channels in the regulation of rat dura and pia artery diameter. Cephalalgia 25:249–260. doi:10.1111/j.1468-2982.2004.00848.x CrossRefPubMed

14.

Kitazono T, Faraci FM, Taguchi H, Heistad DD (1995) Role of potassium channels in cerebral blood vessels. Stroke 26:1713–1723CrossRefPubMed

15.

Jansen-Olesen I, Mortensen CH, El-Bariaki N, Ploug KB (2005) Characterization of KATP-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression. Eur J Pharmacol. 523:109–118. doi:10.1016/j.ejphar.2005.08.028 CrossRefPubMed

16.

Janigro D, West GA, Gordon EL, Winn HR (1993) ATP-sensitive K+ channels in rat aorta and brain microvascular endothelial cells. Am J Phys. 265:C812–C821

17.

Faraci FM, Heistad DD (1998) Regulation of the Cerebral Circulation: Role of Endothelium and Potassium Channels. Physiol Rev. 78:53–97

18.

McPherson GA, Stork AP (1992) The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers. Br J Pharmacol 105:51–58. doi:10.1111/j.1476-5381.1992.tb14209.x CrossRefPubMedPubMedCentral

19.

Ploug KB, Edvinsson L, Olesen J, Jansen-Olesen I (2006) Pharmacological and molecular comparison of KATP channels in rat basilar and middle cerebral arteries. Eur J Pharmacol 553:254–262. doi:10.1016/j.ejphar.2006.09.053 CrossRefPubMed

20.

Ploug KB, Baun M, Hay-Schmidt A et al (2010) Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol 637:109–117. doi:10.1016/j.ejphar.2010.03.027 CrossRefPubMed

21.

Ploug KB, Sørensen MA, Strøbech L et al (2008) KATP channels in pig and human intracranial arteries. Eur J Pharmacol 601:43–49. doi:10.1016/j.ejphar.2008.10.041 CrossRefPubMed

22.

Ploug KB, Amrutkar DV, Baun M et al (2012) K(ATP) channel openers in the trigeminovascular system. Cephalalgia 32:55–65. doi:10.1177/0333102411430266 CrossRefPubMed

23.

Niu K, Saloman JL, Zhang Y, Ro JY (2011) Sex differences in the contribution of ATP-sensitive K+ channels in trigeminal ganglia under an acute muscle pain condition. Neuroscience 180:344–352. doi:10.1016/j.neuroscience.2011.01.045 CrossRefPubMedPubMedCentral

24.

Leoni LAB, Leite GS, Wichi RB, Rodrigues B (2013) Sildenafil: two decades of benefits or risks? Aging Male 16:85–91. doi:10.3109/13685538.2013.801952 CrossRefPubMed

25.

Kruuse C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126:241–247. doi:10.1093/brain/awg009 CrossRefPubMed

26.

Olesen J, Thomsen LL, Lassen LH, Olesen IJ (1995) The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 15:94–100. doi:10.1046/j.1468-2982.1995.015002094.x CrossRefPubMed

27.

Olesen J, Iversen HK, Thomsen LL (1993) Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4:1027–1030CrossRefPubMed

28.

Niehaus L, Gottschalk S, Weber U (1998) Effect of drug-induced vasodilatation of basal brain arteries with nitroglycerin on blood flow velocity and volume flow in the middle cerebral artery. Ultraschall Med 19:225–229. doi:10.1055/s-2007-1000495 CrossRefPubMed

29.

Armstead WM (1996) Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Am J Phys 270:H423–H426

30.

Hempelmann RG, Ziegler A, Mehdorn HM (2001) Role of potassium channels in the relaxation induced by the nitric oxide ( NO ) donor DEA / NO in the isolated rat basilar artery. Neurosci Lett 313:21–24CrossRefPubMed

31.

Murphy ME, Brayden JE (1995) Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol 486 ( Pt 1:47–58. doi:10.1113/jphysiol.1995.sp020789

32.

Yuan Z, Hein TW, Rosa RH, Kuo L (2008) Sildenafil (viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition. Investig Ophthalmol Vis Sci 49:720–725. doi:10.1167/iovs.07-1208 CrossRef

33.

Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J (2008) Role of KATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. Headache 48:1202–1213. doi:10.1111/j.1526-4610.2008.01205.x CrossRefPubMed

34.

Jansen-Olesen I, Gulbenkian S, Engel U et al (2004) Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides 25:2105–2114. doi:10.1016/j.peptides.2004.08.002 CrossRefPubMed

35.

Edvinsson L, Gulbenkian S, Barroso CP et al (1998) Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 19:1213–1225. doi:10.1016/S0196-9781(98)00066-7 CrossRefPubMed

36.

Edvinsson L, Ekman R, Jansen I et al (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7:720–728. doi:10.1038/jcbfm.1987.126 CrossRefPubMed

37.

Olesen J, Diener H, Husstedt IW, et al (2004) Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. Society 1104–1110

38.

Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123. doi:10.1016/S0140-6736(08)61626-8 CrossRefPubMed

39.

Hou M, Xing H, Cai Y et al (2017) The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 18:42. doi:10.1186/s10194-017-0750-1 CrossRefPubMedPubMedCentral

40.

Nelson MT, Huang Y, Brayden JE et al (1990) Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature 344:770–773. doi:10.1038/344770a0 CrossRefPubMed

41.

Quayle JM, Bonev AD, Brayden JE, Nelson MT (1994) Calcitonin gene-related peptide activated ATP-sensitive K+ currents in rabbit arterial smooth muscle via protein kinase a. J Physiol 475:9–13. doi:10.1113/jphysiol.1994.sp020045 CrossRefPubMedPubMedCentral

42.

Nakaya Y, City T (1995) Calcitonin gene-related peptide activates the K + channels of vascular smooth muscle cells via adenylate cyclase. 332–336

43.

Wellman GC, Quayle JM, Standen NB (1998) ATP-sensitive K+ channel activation by calcitonin gene-related peptide and protein kinase a in pig coronary arterial smooth muscle. J Physiol. 507(1):117–129

44.

Bruch L, Rubel S, Kästner A, et al (1998) Pituitary adenylate cyclase activating peptides relax human pulmonary arteries by opening of K ATP and K Ca channels. 586–587

45.

Chalovich JM, Eisenberg E (2005) NIH public access. Biophys Chem 257:2432–2437. doi:10.1016/j.immuni.2010.12.017 Two stage

46.

Amin FM, Asghar MS, Guo S, et al (2011) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. 32:140–149. doi:10.1177/0333102411431333

47.

Amin FM, Hougaard A, Schytz HW et al (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137:779–794. doi:10.1093/brain/awt369 CrossRefPubMed

48.

Erdling A, Sheykhzade M, Maddahi A et al (2013) VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides 47:85–92. doi:10.1016/j.npep.2012.12.005 CrossRefPubMed

49.

Dalsgaard T, Hannibal J, Fahrenkrug J et al (2003) VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 110:179–188. doi:10.1016/S0167-0115(02)00205-7 CrossRefPubMed

50.

Uddman R, Goadsby PJ, Jansen I, Edvinsson L (1993) PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 13:291–297. doi:10.1038/jcbfm.1993.36 CrossRefPubMed

51.

Tong S, Parfenova H, Shibata M et al (1993) Pituitary adenylate cyclase-activating polypeptide dilates cerebral arterioles of newborn pigs. Proc Soc Exp Biol Med 203:343–347CrossRefPubMed

52.

Seki Y, Suzuki Y, Baskaya MK et al (1995) The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol 275:259–266CrossRefPubMed

53.

Zagami AS, Edvinsson L, Goadsby PJ (2014) Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol 1:1036–1040. doi:10.1002/acn3.113 CrossRefPubMedPubMedCentral

54.

Vaudry D, Falluel-morel A, Bourgault S et al (2009) Pituitary Adenylate Cyclase-activating polypeptide and its receptors : 20 years after the discovery. Pept Res 61:283–357. doi:10.1124/pr.109.001370.283

55.

Syed AU, Koide M, Braas KM et al (2012) Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine. J Mol Neurosci 48:574–583. doi:10.1007/s12031-012-9851-0 CrossRefPubMedPubMedCentral

56.

Wienecke T, Olesen J, Ashina M (2010) Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 30:179–190. doi:10.1111/j.1468-2982.2009.01923.x CrossRefPubMed

57.

Ray CJ, Marshall JM (2006) The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J Physiol 570:85–96. doi:10.1113/jphysiol.2005.099390 CrossRefPubMedPubMedCentral

58.

Thomas P, Dixon MS, Winterton SJ, Sheridan DJ (1990) Acute haemodynamic effects of cromakalim in patients with angina pectoris. Br J Clin Pharmacol 29:325–331CrossRefPubMedPubMedCentral

59.

Antihypertensive Effect of Levcromakalim in patients with essential hypertension.pdf

60.

Williams AJ, Lee TH, Vyse T et al (1990) Attenuation of nocturnal asthma by cromakalim. Lancet 336:334–336. doi:10.1016/0140-6736(90)91877-D CrossRefPubMed

61.

von Nguyen P, Holliwell DL, Davis A et al (1991) Effects of the potassium channel activator, cromakalim, on arterial and cardiac responses to norepinephrine, angiotensin II, and isoproterenol in normotensive men. J Cardiovasc Pharmacol 18:797–806CrossRef

62.

Kidney JC, Fuller RW, Worsdell YM et al (1993) Effect of an oral potassium channel activator, BRL 38227, on airway function and responsiveness in asthmatic patients: comparison with oral salbutamol. Thorax 48:130–133. doi:10.1136/thx.48.2.130 CrossRefPubMedPubMedCentral

63.

Fox JS, Whitehead EM, Shanks RG (1991) Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers. Br J Clin Pharmacol 32:45–49CrossRefPubMedPubMedCentral

64.

Hempelmann RG, Barth HL, Mehdorn HM et al (1995) Effects of potassium channel openers in isolated human cerebral arteries. Neurosurgery 37:1146–1153CrossRefPubMed

65.

Ploug KB, Boni LJ, Baun M et al (2008) K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries. Br J Pharmacol 154:72–81. doi:10.1038/bjp.2008.86 CrossRefPubMedPubMedCentral

66.

Zoga V, Kawano T, Liang M-Y et al (2010) KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy. Mol Pain 6:6. doi:10.1186/1744-8069-6-6 CrossRefPubMedPubMedCentral

67.

Olesen J, Jansen-Olesen I (2000) Nitric oxide mechanisms in migraine. Pathol Biol (Paris) 48:648–657

68.

Villalón CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124:309–323. doi:10.1016/j.pharmthera.2009.09.003 CrossRefPubMed

69.

Schytz HW, Birk S, Wienecke T et al (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25. doi:10.1093/brain/awn307 CrossRefPubMed

70.

Kaiser EA, Russo AF (2013) CGRP and migraine: could PACAP play a role too? Neuropeptides 47:451–461. doi:10.1016/j.npep.2013.10.010 CrossRefPubMed

71.

Schytz HW, Schoonman GG, Ashina M (2010) What have we learnt from triggering migraine? Curr Opin Neurol 23:259–265. doi:10.1097/WCO.0b013e328337b884 CrossRefPubMed

72.

Garthwaite J, Charles SL, Chess-Williams R (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336:403–405. doi:10.1038/332141a0 CrossRef

73.

Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain 137:2951–2959. doi:10.1093/brain/awu244 CrossRefPubMed

74.

Dinn RB, Wall M (2006) Tadalafil associated with typical migraine aura without headache. Cephalalgia 26:1344–1346. doi:10.1111/j.1468-2982.2006.01188.x CrossRefPubMed

75.

Road C (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808. doi:10.1177/0333102413485658 CrossRef

76.

Lauritzen M (1994) Pathophysiology of the migraine aura. The spreading depression theory. Brain 117(Pt 1):199–210CrossRefPubMed

77.

Wendt S, Wogram E, Korvers L, Kettenmann H (2016) Experimental cortical spreading depression induces NMDA receptor dependent potassium currents in microglia. J Neurosci 36:6165–6174. doi:10.1523/JNEUROSCI.4498-15.2016 CrossRefPubMed

78.

Staurengo-Ferrari L, Zarpelon AC, Longhi-Balbinot DT et al (2014) Nitroxyl inhibits overt pain-like behavior in mice: role of cGMP/PKG/ATP-sensitive potassium channel signaling pathway. Pharmacol Reports 66:691–698. doi:10.1016/j.pharep.2014.04.003 CrossRef

79.

North RA, Williams JT, Surprenant A, Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Neurobiology 84:5487–5491

80.

Riefflin A, Ayyagari U, Manley SE et al (2015) The effect of glibenclamide on insulin secretion at normal glucose concentrations. Diabetologia 58:43–49. doi:10.1007/s00125-014-3399-1 CrossRefPubMed

81.

Perricone SC, Humphrey SJ, Skaletzky LL, et al (1994) In rats and dogs. 3693–3700

82.

Meisheri KD, Humphrey SJ, Khan SA et al (1993) 4-morpholinecarboximidine-N-1-adamantyl-N’-cyclohexylhydrochloride (U-37883A): pharmacological characterization of a novel antagonist of vascular ATP-sensitive K+ channel openers. J Pharmacol Exp Ther 266:655–665PubMed

83.

Humphrey SJ, Smith MP, Cimini MG et al (1996) Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines. Methods Find Exp Clin Pharmacol 18:247–260PubMed

84.

Shyng SL, Nichols CG (1998) Membrane phospholipid control of nucleotide sensitivity of KATP channels. Science 282(80):1138–1141. doi:10.1126/science.282.5391.1138 CrossRefPubMed

85.

Davies GC, Thornton MJ, Jenner TJ et al (2005) Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J Invest Dermatol 124:686–694. doi:10.1111/j.0022-202X.2005.23643.x CrossRefPubMed

86.

Muiesan G, Fariello R, Muiesan ML, Christensen OE (1985) Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension. Eur J Clin Pharmacol 28:495–499CrossRefPubMed

87.

Laher MS, Hickey MP (1985) Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers. J Int Med Res 13:159–162. doi:10.1177/030006058501300302 CrossRefPubMed

88.

D’Arcy V, Laher M, McCoy D et al (1985) Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. Eur J Clin Pharmacol 28:347–349CrossRefPubMed

89.

Zachariah PK, Sheps SG, Schirger A et al (1986) Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring. Eur J Clin Pharmacol 31:133–141CrossRefPubMed

90.

Sterndorff B, Johansen P (1988) The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice. Acta Med Scand 224:329–336CrossRefPubMed

91.

Goldberg MR (1988) Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 12(Suppl 2):S41–S47CrossRefPubMed

92.

Camm AJ, Maltz MB (1989) A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol 63:61J–65JCrossRefPubMed

93.

Raftery EB, Lahiri A, Hughes LO, Rose EL (1993) A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. Eur heart J 14(Suppl B):35–39CrossRefPubMed

94.

Roland E (1993) Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur heart J 14(Suppl B):48–52CrossRefPubMed

95.

Wolf DL, Ferry JJ, Hearron AE et al (1993) The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers. Eur J Clin Pharmacol 44:27–33CrossRefPubMed

96.

Witchitz S, Darmon JY (1995) Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 9(Suppl 2):237–243CrossRefPubMed

97.

Dunn N, Bm MA, Freemantle S, et al (1999) Safety pro ® le of Nicorandil Ð prescription-event monitoring ( PEM ) study. 205:197–205

98.

Singer DR, Markandu ND, Miller MA et al (1989) Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915). J Hypertens Suppl 7:S294–S295CrossRefPubMed

99.

Suzuki S, Yano K, Kusano S, Hashimoto T (1995) Antihypertensive effect of levcromakalim in patients with essential hypertension. Study by 24-h ambulatory blood pressure monitoring. Arzneimittelforschung 45:859–864PubMed

Title: The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine
Authors: Mohammad Al-Mahdi Al-Karagholi
Jakob Møller Hansen
Johanne Severinsen
Inger Jansen-Olesen
Messoud Ashina
Publication date: 01-12-2017
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2017
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-017-0800-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The K_ATP channel in migraine pathophysiology: a novel therapeutic target for migraine

Abstract

Background

Discussion

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Volumetric abnormalities of thalamic subnuclei in medication-overuse headache

Insomnia in tension-type headache: a population-based study

Prevalence and burden of headache disorders in Lithuania and their public-health and policy implications: a population-based study within the Eurolight Project

Insufficient sleep is prevalent among migraineurs: a population-based study

Alteration of gray matter texture features over the whole brain in medication-overuse headache using a 3-dimentional texture analysis

Experts’ opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents